Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Terrence Lee Fisher, Elizabeth E. Evans, Crystal L. Mallow, Amber Foster, Megan Boise, Ernest Smith, John E. Leonard, Marya F. Chaney, Joseph Thaddeus Beck, Steven Jeffrey Hager, Tarek Mekhail, Nagashree Seetharamu, Megan Baumgart, Nabil F. Saba, Conor Ernst Steuer, Douglas Adkins, Barbara Burtness, Maurice Zauderer
Institutions: Vaccinex (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Highlands Oncology Group, California Cancer Associates for Research and Excellence, Florida Hospital Cancer Institute, Northwell Health, University of Rochester, Emory University, Winship Cancer Institute, Washington University in St. Louis, Yale Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281640375